We do not support your browser. Please take a moment and upgrade to the most recent version of Internet Explorer.

UCLA Biodesign Sets Up National Registry to Understand COVID-19 Risks to Pregnant Women and Newborns



UCLA CTSI News Archive

A new national registry has been launched by specialists in obstetrics, gynecology and reproductive sciences at UCLA Health and the University of California, San Francisco, to determine COVID-19's possible effects on pregnant women and newborns.

The registry for the PRIORITY study–Pregnancy CoRonavIrus Outcomes RegIsTrY–is enrolling pregnant women and those who have been pregnant or postpartum within the past six weeks who have a confirmed diagnosis of COVID-19 or are being evaluated for that possibility. UCLA Health's participation is aligned with the goals of UCLA Biodesign, a program that promotes health care innovation and partnerships that develop novel tools and technologies.

"We expect this registry to provide data that will be critical in helping to improve care for pregnant women during this global pandemic," said Yalda Afshar, MD, PhD, an obstetrician/gynecologist at UCLA Health and a UCLA Biodesign Fellow, who is co-principal investigator of the study. 

Read the full UCLA press release

UCLA CTSI is one of the proud partners of UCLA Biodesign.  

More Information: 
CBS Newspath: Researchers seek COVID-19 effects on pregnancy